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Abstract
Objective—To examine longitudinal bidirectional associations between two depressive symptom
clusters – the cognitive-affective and somatic-vegetative clusters – and insulin resistance, a marker
of pre-diabetes.
Methods—Participants were 269 adults aged 50–70 years without diabetes enrolled in the
Pittsburgh Healthy Heart Project, a prospective cohort study. At baseline and 6-year visits,
participants completed the Beck Depression Inventory-II (BDI-II) and underwent a blood draw to
quantify fasting insulin and glucose. We examined baseline BDI-II total, cognitive-affective, and
somatic-vegetative scores as predictors of 6-year change in the homeostatic model of assessment
(HOMA) score, an estimate of insulin resistance computed from fasting insulin and glucose. We
also examined baseline HOMA score as a predictor of 6-year change in BDI-II total and subscale
scores.
Results—Regression analyses, adjusted for demographic factors and baseline HOMA score,
revealed that the baseline BDI-II somatic-vegetative score (β = .14, p = .025), but not the
cognitive-affective (β = .001, p = .98) or total (β = .10, p = .11) scores, predicted 6-year HOMA
change. This result persisted in models controlling for anxiety symptoms and hostility. Several
factors were examined as candidate mediators; however, only change in body mass index (BMI)
was a significant mediator (p = .042), accounting for 23% of the observed association. Baseline
HOMA score did not predict 6-year change in BDI-II total or subscale scores (all ps >.56).
Conclusions—Among adults aged 50–70 years, the somatic-vegetative symptoms of depression
(e.g., fatigue, sleep disturbance, and appetite changes) may worsen insulin resistance and increase
diabetes risk, partly, by increasing BMI.
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Introduction
A growing body of evidence links depression and type 2 diabetes (1–3). Specifically, studies
report that depressed adults have a 37–60% increased risk of developing diabetes than
nondepressed adults (4, 5), which may partially explain the elevated cardiovascular disease
risk in this population (6). In addition, individuals with diabetes exhibit a 15–24% increased
risk of developing depression compared to the general population (5, 7). Although not well
understood, both behavioral and physiologic mechanisms have been proposed as potential
explanations of this bidirectional relationship. For instance, the poor health behaviors (2)
and the neuroendocrine (8) and inflammatory (9) activation associated with depression could
promote the development of diabetes (10). In the other direction, a sense of threat or loss
following a diabetes diagnosis and the high self-management burden of the condition could
increase the risk of depression (5).
Recent investigations have also tested whether this association is present in pre-diabetes, as
identified by the sentinel risk marker of insulin resistance. Insulin resistance occurs when
peripheral insulin receptors exhibit decreased sensitivity to insulin, leading to reduced
glucose uptake in fat, muscle, and liver tissue, and consequently, increased glucose levels in
the blood stream (11). In a recent meta-analysis of 18 studies, a small but significant
association (d = .19) between depressive symptom severity and insulin resistance was found
(12). A major limitation, however, was that 17 of 18 studies used a cross-sectional design.
The sole prospective study examined one direction of the depression-insulin resistance
relationship, finding that depressive symptom severity was associated with the average of
the baseline and 3-year homeostatic model of assessment (HOMA) scores but not with 3-
year HOMA change (13). Due to the lack of prospective studies, it is not clear whether (a)
depressive symptoms contribute to the onset of insulin resistance or (b) insulin resistance
promotes the development of depressive symptoms. Determining the directionality of this
relationship could have significant implications. If (a) is supported, treating depression in
patients at greater diabetes risk might prevent or delay the onset of this metabolic condition,
whereas if (b) is supported, elevations in depressive symptoms among patients at greater
diabetes risk might be a sign of subclinical disease progression.
In other literatures, researchers have also begun to compare the relative importance of
depressive symptom clusters in predicting health outcomes, such as cardiovascular risk (14)
and prognosis (15). Depression, a multidimensional construct, consists of affective (e.g.,
depressed mood), cognitive (e.g., concentration difficulties), behavioral (e.g., psychomotor
retardation), and somatic (e.g., fatigue) symptom clusters (16). To our knowledge, no studies
have examined whether particular depressive symptom clusters are stronger predictors or
consequences of insulin resistance. Pinpointing the key clusters could help to elucidate the
mechanisms underlying the depression-insulin resistance relationship (by increasing or
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decreasing the plausibility of candidate mediators) and could help to maximize the potential
diabetes benefits of depression treatment (by delivering interventions specifically targeting
the key clusters).
To fill the aforementioned gaps in the literature, we examined data collected as part of the
Pittsburgh Healthy Heart Project (PHHP), a 6-year prospective cohort study of healthy,
adults aged 50–70 years (17). Our primary objective was to examine longitudinal
bidirectional associations between two depressive symptom clusters – the cognitive-
affective and somatic-vegetative clusters – and insulin resistance estimated by the HOMA
score (18). We also examined whether any detected associations remained after adjustment
for overlapping emotional factors. Because depression, anxiety, and hostility are moderately
correlated (19–21) and have each been associated with insulin resistance in isolation (22,
23), it is not known whether the depressive symptoms-insulin resistance association exists
independently of other emotional factors (24). Finally, we examined several behavioral
(body mass index [BMI], smoking, alcohol intake, physical activity, and sleep duration) and
physiologic factors (inflammatory markers) as mediators of any detected associations. These
factors have been linked to both depressive symptoms and insulin resistance in past studies
and have been hypothesized as candidate mechanisms underlying the depression-insulin
resistance relationship (10, 11, 25).
Methods
Participants
Participants enrolled in the parent PHHP study were 464 healthy adults. The PHHP was
approved by the University of Pittsburgh Institutional Review Board. Participants provided
written informed consent and were paid $700 for attending all study visits. Details regarding
participant recruitment and the inclusion/exclusion criteria are reported elsewhere (17, 26).
Briefly, individuals were eligible if they were between the ages of 50 and 70 years; reported
no history of chronic disease, bipolar disorder, or schizophrenia; and reported no use of
medications with lipid-lowering, antihypertensive, or autonomic effects. Exceptions to the
chronic disease exclusion criterion were that adults with a diabetes diagnosis who were not
taking insulin and adults with mild to moderate rheumatoid arthritis were allowed to enroll
in the PHHP.
The 296 adults (64% of those enrolled) who attended the follow-up visits approximately six
years after the baseline visits were considered the eligible cohort for the present study.
Participants who attended the follow-up visits were older [t(462) = −2.08, p = 0.038], more
educated [t(461) = −2.63, p = 0.009], more likely to be White [χ2(1, N=463) = 10.18, p < .
001], and had lower depressive symptom severity [t(385) = −1.97, p = 0.049] than those
who did not attend these visits; however, group differences were not observed for sex or
baseline HOMA scores. From the eligible cohort, we excluded 11 adults who had missing
data for the depressive symptoms, glucose, or insulin variables at baseline or the 6-year
follow-up. Of the remaining 285 participants, we excluded the four adults enrolled in the
PHHP with a diabetes diagnosis but who were not taking insulin at baseline. We then
excluded an additional 11 individuals who reported receiving a new diabetes diagnosis or
taking a diabetes medication during the follow-up interval, as assessed at the 6-year medical
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interview. For the remaining 270 participants, we examined skewness and kurtosis values of
our depressive symptom and insulin resistance variables at baseline and follow-up. These
values were all within the acceptable ranges (27) with one exception: the kurtosis value for
baseline HOMA (15.04) was greater than 10. A single baseline HOMA value was found to
be disconnected from the distribution; removing this case resulted in an acceptable kurtosis
value (2.55). Consequently, this case was excluded from all analyses, leaving a final sample
of 269 participants (see Table 1 for demographic characteristics).
Measures and Procedure
Overview—At baseline (1998–2000), participants attended 11 visits during a 5-month
period: a medical screen, seven visits for ambulatory monitoring training and questionnaire
assessments, one visit for reactivity testing, and two visits for ultrasound assessments.
Approximately six years later (M = 6.3, SD = 0.2), participants attended six follow-up visits,
during which they completed a medical update and other assessments similar to those
completed at baseline.
Depressive symptoms—At the third baseline visit and third follow-up visit six years
later, participants completed the Beck Depression Inventory-II (BDI-II; 18) on a computer.
The BDI-II is a widely used self-report measure of depressive symptom severity. The
measure consists of 21 items and has demonstrated high internal consistency, test-retest
reliability, and construct validity (28, 29). In addition to calculating the baseline and 6-year
total scores, we computed BDI-II subscale scores by summing the items loading on the two
factors identified by Dozois and colleagues (29). Those researchers performed an
exploratory factor analysis using maximum likelihood extraction with oblique rotation on a
sample of 1,022 younger adults and identified two moderately correlated factors that
accounted for 46% of the variance. The cognitive-affective factor consisted of Items 1
(sadness), 2 (pessimism), 3 (past failure), 5 (guilty feelings), 6 (punishment feelings), 7
(self-dislike), 8 (self-criticalness), 9 (suicidal thoughts), 13 (indecisiveness), and 14
(worthlessness), and the somatic-vegetative factor consisted of Items 4 (loss of pleasure), 10
(crying), 11 (agitation), 12 (loss of interest), 15 (loss of energy), 16 (changes in sleep), 17
(irritability), 18 (changes in appetite), 19 (concentration), 20 (tiredness-fatigue), and 21 (loss
of interest in sex) (29). In our sample, the cognitive-affective and somatic-vegetative factors
demonstrated adequate internal consistency (Cronbach’s α = .66 and .69, respectively). We
decided to use the results of Dozois et al. (29) instead of other factor analyses of the BDI-II
(28, 30) for the following reasons: (a) their sample (presumably mentally and physically
healthy, community-dwelling adults) more closely resembled ours than other samples (e.g.,
psychiatric or medical patients), (b) their analyses had methodological strengths, including
utilizing a larger sample, cross-validating their results, and establishing that their factor
structure was similar for men and women, and (c) we have used this approach in past
analyses of the PHHP data (26, 31, 32) and want to maintain consistency across reports. We
also calculated 6-year change scores by subtracting the baseline total and subscale scores
from their corresponding follow-up scores.
Insulin Resistance—At the first baseline visit and the first follow-up visit six years later,
participants underwent a blood draw between 8:30 AM and 11:30 AM. They were asked to
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fast and to avoid caffeine for 12 hours prior to the start of their baseline visit, which
occurred between 8:00 AM and 10:00 AM. If a participant indicated that the fasting
instructions were not followed, the blood draw was rescheduled. To assess serum glucose
and insulin, blood samples were collected in red-top Vacutainer tubes by standard venous
phlebotomy, allowed to clot at room temperature for 40 minutes, and refrigerated for up to
three hours until centrifuged at 4°C. Following centrifugation, serum aliquots were frozen at
−20°C until assay within 30 days at the University of Pittsburgh Heinz Nutrition Laboratory.
Fasting serum glucose was measured by standard colorimetry (33), and fasting serum insulin
was measured by radioimmunoassay.
We computed baseline and 6-year HOMA scores from the corresponding insulin and
glucose values using this formula: [(fasting insulin (uU/ml) * fasting glucose (mg/dl)/405]
(18). Greater HOMA scores denote lower insulin sensitivity or higher insulin resistance
(13). Estimates of insulin resistance from HOMA and the gold-standard euglycemic clamp
method have found to correlate well with one another (Rs = 0.85–0.88; 34, 35). HOMA is
often used as a measure of basal insulin resistance in epidemiologic studies and is
appropriate for assessing change in insulin sensitivity over time (36). We calculated 6-year
HOMA change scores by subtracting the baseline score from the follow-up score.
Other factors—We included several other factors as covariates in our analyses. These
factors were assessed during the baseline visits through questionnaires, a blood draw, and
anthropometric measurements. The demographic factors were: age (years), sex (0 = male, 1
= female), race/ethnicity (1 = White, 2 = Black, 3 = Asian, 4 = Hispanic, 5 = Other), and
education level (1 = high school or less, 2 = technical school or some college, 3 =
Bachelor’s degree, 4 = Master’s degree or higher). As only six individuals selected the
Asian, Hispanic, or Other categories, the race/ethnicity variable was recoded to create a
binary variable (0 = White, 1 = non-White).
Other negative emotional factors included were anxiety symptoms and hostility. At the third
baseline visit, participants completed the Beck Anxiety Inventory (BAI; 37, 38), an
established 21-item measure of anxiety symptom severity. At the fourth baseline visit,
participants completed the Cook-Medley Hostility Scale (Ho Scale; 39), a questionnaire that
measures several components of hostility, including cynicism, hostile attributions, hostile
affect, aggressive responding, and social avoidance. We used the 27-item version of the Ho
Scale instead of the 50-item version because this version has been shown to be a stronger
predictor of health outcomes (39). Both the BAI and Ho Scales possess good psychometric
properties (37, 40–42).
The behavioral candidate mediators were BMI, smoking status (0 = current nonsmoker, 1 =
current smoker), daily alcohol intake, physical activity, and self-reported sleep duration.
BMI was calculated as weight in kilograms divided by the square of height in meters
(kg/m2). Daily alcohol intake (g/day) was calculated using the quantity–frequency method
(43). Physical activity was computed from participants’ responses on the Paffenbarger
Physical Activity Questionnaire (44). Specifically, the number of reported blocks walked
and stairs climbed per day, and all reported activities (e.g., running, boxing, hiking,
swimming etc.) were converted to kilocalories per week and then summed. Self-reported
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sleep duration was assessed using Item 4 of the Pittsburgh Sleep Quality Index (45). We log
transformed (Xi + 1) daily alcohol intake and physical activity variables to normalize the
distributions by reducing positive skew.
Lastly, the physiologic candidate mediators were the inflammatory markers, C-reactive
protein (CRP) and interleukin-6 (IL-6). To assess inflammatory markers, blood samples
were collected in tubes with no additives, were stored at room temperature for 40 minutes,
and then were refrigerated until they were centrifuged within three hours of collection to
isolate serum. Serum aliquots were frozen at −70 °C until time of assay at the Laboratory for
Clinical Biochemistry Research at the University of Vermont. CRP was measured with a
BNII nephelometer using a particle-enhanced immunonephelometric assay (Dade Behring,
Deerfield, IL), and IL-6 was measured using ultra-sensitive enzyme-linked immunosorbent
assay kits (R&D Systems, Minneapolis, MN). We excluded individuals with CRP ≥ 10
mg/L (n = 13), as levels above this value are likely due to acute infection or trauma and thus
not indicative of chronic inflammation (46). We log transformed (Xi + 1) baseline CRP and
IL-6 variables to normalize the distributions by reducing positive skew.
All behavioral and physiologic candidate mediators, with the exception of sleep duration,
were assessed during the 6-year follow-up visits in a manner identical to the baseline visits.
We calculated 6-year change in these candidate mediators by subtracting the baseline scores
from their corresponding follow-up scores.
Data Analyses
To determine whether (a) baseline depressive symptoms predict 6-year change in HOMA
score and (b) baseline HOMA score predicts 6-year change in depressive symptoms, we
conducted two sets of linear regression analyses. In the first set, we constructed three
models, with BDI-II total score, cognitive-affective score, and somatic-vegetative score as
the independent variables in separate models and HOMA change score as the dependent
variable. In each model, we also entered age, sex, race/ethnicity, education, and baseline
HOMA score (demographics-adjusted models). In the second set, we constructed three
additional models, with baseline HOMA score as the independent variable and BDI-II total
change score, cognitive affective change score, and somatic-vegetative change score as the
dependent variables in separate models. Each of these models also included age, sex, race/
ethnicity, education, and the corresponding baseline BDI-II score (demographics-adjusted
models).
For any observed relationships, we conducted three sets of additional analyses. First, we
examined whether the observed relationship remained after adjustment for anxiety
symptoms and hostility by adding BAI and Ho scores one at a time into the demographics-
adjusted models. Second, we evaluated the influence of candidate mediators measured at
baseline on any observed associations by entering baseline BMI, smoking, alcohol intake,
physical activity, sleep duration, CRP, and IL-6 one at a time to the demographics-adjusted
models. Third, we evaluated the influence of 6-year change in these candidate mediators.
We could not examine change in smoking because only four participants quit smoking
during follow-up. The 6-year change variables were entered one at a time to the
demographics-adjusted models that also included the baseline candidate mediator variable.
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For the last two sets of analyses, we computed Sobel tests (Aroian version) to assess
whether these variables statistically mediated any observed relationships (47, 48). For
significant mediators, the percent change in the effect size of any observed relationships
after adjustment for the mediator was computed as (Badjusted − Bunadjusted)/Bunadjusted × 100,
where Badjusted is the unstandardized coefficient for the BDI-II variable from the model with
the mediator, and Bunadjusted is the same unstandardized coefficient from the model without
the mediator. All analyses were performed using SPSS statistical software (version 20).
Results
As shown in Table 1, participants in our sample were older, were predominantly white, and
had higher education levels. HOMA, BDI-II total, and somatic-vegetative scores increased
significantly from baseline to 6-year follow-up (ps < .001), while the cognitive-affective
score did not (p = .069).
Depressive symptoms as predictors of 6-year change in HOMA score
Results of the demographic-adjusted models revealed that neither the BDI-II total score (p
= .11) nor the cognitive-affective score (p = .98) predicted changes in HOMA over time
(Table 2). In contrast, the somatic-vegetative score did predict 6-year increases in the
HOMA score (β = .14, p = .025). None of the demographic variables included in this model
were associated with HOMA change (all ps > .11). Table S1 (Supplemental Digital Content
1) presents the unadjusted correlations between the baseline depressive symptom variables
and their change scores and the baseline glucose, insulin, and HOMA scores and their
change scores.
The somatic-vegetative score remained predictive of 6-year increases in HOMA when the
BAI score (somatic-vegetative score: β = .18, p = .009; BAI total: β = −.10, p = .13) and the
Ho score (somatic-vegetative score: β = .14, p = .027; Ho total: β = −.01, p = .89) were
added to separate models, although neither anxiety symptoms nor hostility predicted HOMA
change. These results indicate that the association between the somatic-vegetative symptoms
and HOMA change is independent of comorbid anxiety symptoms and hostility.
Analyses examining the influence of baseline candidate mediators on the observed
association revealed that the somatic-vegetative score remained predictive of 6-year
increases in HOMA when BMI (β = .16, p = .008), smoking status (β = .14, p = .024),
alcohol intake (β = .15, p = .018), and sleep duration (β = .14, p = .019) were entered, and it
fell short of significance when physical activity (β = .10, p = .11), CRP (β = .12, p = .069),
and IL-6 (β = .12, p = .051) were entered one at a time to the demographic-adjusted models.
Sobel tests indicated that none of the baseline candidate mediators statistically mediated the
observed relationship (all ps > .32).
A similar set of analyses examining the influence of 6-year change in the candidate
mediators indicated that that the somatic-vegetative score remained predictive of 6-year
increases in HOMA when BMI change (β = .12, p = .039), alcohol intake change (β = .15, p
= .019), and CRP change (β = .13, p = .044) were entered, and it fell short of significance
when physical activity change (β = .12, p = .062) and IL-6 change (β = .11, p = .10) were
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entered one at a time into the demographics-adjusted model that also included the baseline
candidate mediator. There was no evidence of statistical mediation by any of these variables
(all ps for Sobel tests > .19) with the exception of BMI change (z = 2.03, p = .042).
Adjusting for BMI change reduced the magnitude of the association between the somatic-
vegetative score and HOMA score by 23%. Because the somatic-vegetative score was
positively related to BMI change (β = .14, p = .018) and BMI change was positively related
to HOMA change (β = .25, p < .001), these results suggest that increases in BMI partially
explain the link between the somatic-vegetative symptoms and increases in HOMA score
over time.
HOMA score as predictor of 6-year change in depressive symptoms
Table 3 shows the results of demographic-adjusted models examining HOMA score as a
predictor of 6-year change in the depressive symptom variables. These analyses revealed
that baseline HOMA score did not predict 6-year change in the BDI-II total score (p = .70),
the cognitive-affective score (p = .98), or the somatic-vegetative score (p = .56). None of the
demographic variables included in these models was associated with any of the depressive
symptom variables (all ps > .095).
Discussion
The primary objective of the present study was to examine the longitudinal bidirectional
associations between two depressive symptom clusters and insulin resistance. In this sample
of healthy adults aged 50–70 years, the somatic-vegetative cluster, but not the cognitive-
affective cluster, predicted increases in a well-established estimate of insulin resistance, the
HOMA score, over a 6-year period. In the other direction, insulin resistance at baseline did
not predict increases in either the cognitive-affective or the somatic-vegetative clusters over
the follow-up period. Total depressive symptom severity was unrelated to insulin resistance
in either direction. The prospective association between the somatic-vegetative symptoms
and 6-year increases in insulin resistance was independent of the overlapping emotional
factors of anxiety symptoms and hostility. Several behavioral and physiologic factors were
examined as candidate mediators; however, only BMI change was a significant mediator,
accounting for almost one quarter of the association of somatic-vegetative symptoms with
insulin resistance increases. Taken together, these results suggest that the somatic-vegetative
symptoms of depression may worsen insulin resistance and increase diabetes risk, in part, by
increasing BMI.
While there exist several cross-sectional studies on the association between depressive
symptoms and insulin resistance, only two have examined this relationship longitudinally. In
the depressive symptoms-to-insulin resistance direction, Everson-Rose et al. (13) found that
elevated depressive symptoms were associated with a higher average HOMA score over a 3-
year period, but not with increases in HOMA score over time, as was found in the present
study. This inconsistent result may be due to dissimilar sample characteristics; that study
used a sample of middle-aged women. In the insulin resistance-to-depressive symptoms
direction, Lawlor et al. (49) followed 2,203 middle-aged British men over a 14-year period.
Consistent with our results, these researchers found that insulin resistance at baseline did not
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predict depressive symptoms 5, 10, or 14 years later. Our results also align with recent meta-
analytic findings. Kan et al. (12) reported a small association (d = .19) between depression
and insulin resistance, which was attenuated in analyses adjusted for body weight. An
important caveat, however, is that this meta-analysis almost exclusively included cross-
sectional studies and, therefore, cannot speak to the directionality of this relationship. Our
findings add to this literature (a) by suggesting a direction for this relationship (i.e.,
depressive symptoms to insulin resistance) and (b) by indicating that the somatic-vegetative
cluster may be largely responsible for this prospective link.
What factors might explain why the somatic-vegetative cluster of depressive symptoms, but
not the cognitive-affective cluster, predicted increases in insulin resistance over time? One
possibility is that the somatic-vegetative symptoms – such as fatigue, sleep disturbance, and
appetite changes – contribute more to deleterious physical activity and dietary behaviors
than do the cognitive-affective symptoms, resulting in a sedentary lifestyle, high caloric
intake, and ultimately obesity. A consequence of obesity, particularly central adiposity, is
the release of excess cortisol, which increases glucose production and can contribute to
insulin resistance (10). Another consequence of obesity is increased release of inflammatory
markers, a key component in the pathogenesis of insulin resistance (50), from visceral
adipose tissue. Our finding that BMI change was a partial mediator of the association
between the somatic-vegetative symptoms and 6-year increases in insulin resistance is
consistent with this first possibility. A second possibility involves activation of the innate
immune system via pathways other than increased adiposity, such as depression-related
hypothalamic-pituitary-adrenal axis dysregulation (51) or autonomic dysfunction (52).
Individuals with depressive disorders or elevated symptoms exhibit higher levels of
inflammatory markers relative to nondepressed individuals, independent of BMI (25).
Moreover, studies have reported that the depression-inflammation association is driven
primarily by the somatic symptoms (31, 53). Our finding that inflammatory markers
(baseline level or 6-year change) were not mediators conflicts with this second possibility;
however, we examined only two markers of systemic inflammation, CRP and IL-6.
A third possibility is that somatic-vegetative cluster predicted increases in insulin resistance
because these symptoms are due to a condition other than subsyndromal depression that also
promotes insulin resistance, such as insomnia, sleep apnea, or another age-related condition
(54, 55). The low depressive symptom scores in our sample increase the likelihood that
these symptoms may be signs of another condition, at least in some individuals. It is worth
noting, however, that the somatic-vegetative score remained predictive of 6-year increases in
HOMA after adjustment for baseline sleep duration and that PHHP participants were
generally free of chronic conditions at enrollment. A final possibility is that methodological
factors may have contributed to our results. Older adults are more likely to report somatic
versus cognitive symptoms of depression, perhaps due to a reporting bias or a difference in
the phenomenology of depression in this population (56). In line with these findings, the
mean and standard deviation at baseline were greater for the somatic-vegetative subscale (M
= 2.83, SD = 2.79) than the cognitive-affective subscale (M = 1.04, SD = 1.65). This
increased variability could be partially responsible for the greater predictive utility of the
somatic-vegetative subscale.
Khambaty et al. Page 9
Psychosom Med. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
We did not find a prospective relationship between insulin resistance and change in
depressive symptoms over time. One potential explanation for this finding is the
“psychological burden hypothesis” (57), which posits that the awareness and burden of
being diagnosed with and managing a chronic condition may result in higher levels of
depressive symptoms (7). Accordingly, adults who have insulin resistance but who have not
yet been diagnosed with diabetes would not experience this burden and, consequently, may
not exhibit elevated depressive symptoms. In support of this notion, a recent meta-analysis
found that individuals with impaired glucose metabolism and undiagnosed diabetes
experienced rates of depression similar to individuals with normal glucose metabolism (7).
In contrast, individuals with previously diagnosed type 2 diabetes experienced increased
rates of depression compared to individuals with either undiagnosed diabetes or impaired
glucose metabolism (7).
In addition to its strengths (e.g., prospective design, validated measures of depressive
symptoms and insulin resistance, and bidirectional examination of the key association),
limitations of our study should be noted. First, due to an oversight in constructing the
computerized version of the BDI-II, the time frame for rating the severity of symptoms was
erroneously entered as “during the past week” (the time frame for the original BDI), rather
than “the past 2 weeks” (the time frame for the BDI-II). The likely result of this oversight,
however, was that the true BDI-II score was underestimated, given that individuals tend to
score lower on the original BDI than on the BDI-II (29). The subsequent decrease in the
variability of the BDI-II scores may have artificially weakened the relationship between
depressive symptoms and 6-year HOMA change. Second, given that our sample was fairly
homogeneous, consisting of healthy, predominantly White older adults, our results may not
generalize to younger populations, older populations with chronic medical conditions, or
other racial groups.
Overall, we found that (a) greater somatic-vegetative symptoms of depression (e.g., fatigue,
sleep disturbance, and appetite changes) predict increases in insulin resistance over time and
(b) increases in BMI partially mediate this relationship. Our results suggest that adults aged
50–70 years experiencing these symptoms may be at an increased risk of developing insulin
resistance and, subsequently, type 2 diabetes. These findings contribute to our yet limited
knowledge of the pathways underlying the depression-diabetes relationship and, if replicated
in future studies, would support the development and testing of interventions targeting the
somatic-vegetative symptoms to prevent insulin resistance and type 2 diabetes.
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Table 1
Characteristics of Participants
Variable Baseline 6-Year Follow-up
Demographic factors
 Age, years 60.7 (4.6) ---
 Sex, % female 55.0 ---
 Race/ethnicity, % non-White 14.1 ---
 Education level, %
  High school or less 22.3 ---
  Technical school or some college 25.7 ---
  Bachelor’s degree 25.7 ---
  Master’s degree or higher 26.4 ---
Depressive symptom variables
 BDI-II Total 3.8 (3.9) 5.1 (5.1)
 Baseline BDI-II Cognitive-Affective Cluster 1.0 (1.6) 1.3 (2.3)
 Baseline BDI-II Somatic-Vegetative Cluster 2.8 (2.8) 3.8 (3.4)
Insulin resistance variables
 Glucose, mg/dl 90.3 (8.2) 99.1 (13.8)
 Insulin, uU/ml 11.2 (4.3) 13.2 (6.2)
 HOMA score 2.5 (1.1) 3.3 (1.9)
Other negative emotional factors
 Beck Anxiety Inventory (possible range: 0–63; N = 268) 5.0 (4.7) ---
 Cook-Medley Hostility Scale (possible range: 0–27; N = 268) 8.0 (4.1) ---
Candidate mediators
 Body mass index, kg/m2 27.5 (4.6) 27.8 (4.8)
 Smoking status, % current smokers 5.6 4.1
 Daily alcohol intake, g/day (6-year follow-up: N = 265) 6.5 (9.8) 11.9 (16.8)
 Physical activity, kilocalories/week (Baseline: N = 266; 6-year follow-up: N = 259) 6497.6 (15400.7)a 6918.9 (9488.0)b
 Self-reported sleep duration, hours 6.9 (1.1) ---
 Serum CRP, mg/L (Baseline: N = 247; 6-year follow-up: N = 238) 2.1 (1.9) 1.7 (1.8)
 Serum IL-6, pg/ml (Baseline: N = 260; 6-year follow-up: N = 257) 1.9 (1.6) 2.8 (2.5)
Note. N = 269, except where otherwise indicated. Continuous data are presented as mean (SD), and categorical data are presented as a percentage.
BDI-II = Beck Depression Inventory-II; CRP = C-reactive protein; HOMA = Homeostatic Model of Assessment; IL-6 = interleukin-6.
a219,079 kilocalories/week is an extreme data point (next highest value is 61,339 kilocalories/week). The median value for physical activity was
3088.0 kilocalories/week. Because either inclusion or exclusion of this data point necessitated log transformation to reduce positive skew and led to
the same pattern of results, it was included in the baseline physical activity analysis.
b76,921 kilocalories/week is an extreme data point (next highest value is 48,794 kilocalories/week). The median value for physical activity was
3452.8 kilocalories/week. Because either inclusion or exclusion of this data point led to the same pattern of results, it was included in the 6-year
change physical activity analysis.
Psychosom Med. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Khambaty et al. Page 16
Ta
bl
e 
2
R
eg
re
ss
io
n 
A
na
ly
se
s E
xa
m
in
in
g 
D
ep
re
ss
iv
e 
Sy
m
pt
om
s a
s P
re
di
ct
or
s o
f 6
-y
ea
r C
ha
ng
e i
n 
H
O
M
A
 S
co
re
D
em
og
ra
ph
ic
s-
ad
jus
ted
 M
od
els
a
B
SE
 B
β
R
2
ΔR
2
ΔF
B
as
el
in
e 
BD
I-I
I T
ot
al
.
04
.
03
.
10
.
02
.
01
2.
56
B
as
el
in
e 
BD
I-I
I C
og
ni
tiv
e-
A
ffe
ct
iv
e 
Sc
or
e
.
00
1
.
06
.
00
1
.
01
.
00
.
00
B
as
el
in
e 
BD
I-I
I S
om
at
ic
-V
eg
et
at
iv
e 
Sc
or
e
.
08
.
03
.
14
*
.
03
.
02
5.
07
No
te
. N
 
=
 2
69
. B
D
I-I
I =
 B
ec
k 
D
ep
re
ss
io
n 
In
ve
nt
or
y-
II;
 H
O
M
A
 =
 H
om
eo
sta
tic
 M
od
el
 o
f A
ss
es
sm
en
t.
a
A
dju
ste
d f
or 
ag
e, 
sex
, ra
ce/
eth
nic
ity
, e
du
cat
ion
, a
nd
 ba
sel
ine
 H
OM
A 
sco
re.
*
p 
< 
.0
5
Psychosom Med. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Khambaty et al. Page 17
Ta
bl
e 
3
R
eg
re
ss
io
n 
A
na
ly
se
s E
xa
m
in
in
g 
H
O
M
A
 S
co
re
 a
s a
 P
re
di
ct
or
 o
f 6
-y
ea
r C
ha
ng
e i
n 
D
ep
re
ss
iv
e S
ym
pt
om
s
D
em
og
ra
ph
ic
s-
ad
jus
ted
 M
od
els
a
B
SE
 B
β
R
2
ΔR
2
ΔF
BD
I-
II
 T
ot
al
 S
co
re
 C
ha
ng
e
 
B
as
el
in
e 
H
O
M
A
 S
co
re
.
10
.
25
.
02
.
09
.
00
.
14
BD
I-
II
 C
og
ni
tiv
e-
Af
fec
tiv
e S
co
re 
Ch
an
ge
 
B
as
el
in
e 
H
O
M
A
 S
co
re
.
00
4
.
12
.
00
2
.
10
.
00
.
00
1
BD
I S
om
at
ic
-V
eg
et
at
iv
e 
Sc
or
e 
Ch
an
ge
 
B
as
el
in
e 
H
O
M
A
 S
co
re
.
10
.
17
.
03
.
15
.
00
1
.
34
No
te
. N
 
=
 2
69
. B
D
I-I
I =
 B
ec
k 
D
ep
re
ss
io
n 
In
ve
nt
or
y-
II;
 H
O
M
A
 =
 H
om
eo
sta
tic
 M
od
el
 o
f A
ss
es
sm
en
t.
a
A
dju
ste
d f
or 
ag
e, 
sex
, ra
ce/
eth
nic
ity
, e
du
cat
ion
, a
nd
 re
spe
cti
ve
 ba
sel
ine
 B
DI
-II
 sc
ore
*
p 
<
 .0
5
Psychosom Med. Author manuscript; available in PMC 2015 June 01.
